Multiple clinical trials were undertaken to assess the effectiveness of EGFR inhibitors, such as gefitinib and erlotinib, in patients with R/M NPC who had previously undergone chemotherapy [47–49]. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.